CN Patent

CN121038782A — 具有改善的生物利用度的仑伐替尼组合物

Assigned to Stard Pharmaceuticals · Expires 2025-11-28 · 0y expired

What this patent protects

本发明涉及包含治疗有效剂量的仑伐替尼盐和钾碳酸盐、特别是碳酸氢钾的药物组合物，其中，仑伐替尼盐比钾碳酸盐的重量比选自1:0.3至1:3.0的范围。

USPTO Abstract

本发明涉及包含治疗有效剂量的仑伐替尼盐和钾碳酸盐、特别是碳酸氢钾的药物组合物，其中，仑伐替尼盐比钾碳酸盐的重量比选自1:0.3至1:3.0的范围。

Drugs covered by this patent

afatinib-dimaleate (AFATINIB DIMALEATE)

Patent Metadata

Patent number: CN121038782A
Jurisdiction: CN
Classification: —
Expires: 2025-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Stard Pharmaceuticals
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.